CXCL10 and hepatocellular carcinoma: When we categorized the patients with BCLC stage C HCC into two groups based on serum CXCL10‐2c levels, the CXCL10‐2c high group (≥690 pg/mL) included a higher proportion of initial responders than the CXCL10‐2c low group (<690 pg/mL, p = 0.027; Table 3).